As Chief of Pulmonary and Critical Care, I oversee all of our Divisional research at the University of Texas Health Science Center – San Antonio (UTHSCSA). We are involved in basic and clinical research in the evaluation of pulmonary infection, chronic obstructive lung disease, asthma, lung transplantation and pulmonary fibrosis. My primary area of interest is supported by the National Institute of Health and the National Institute of Allergy and Infectious Diseases in the area of chronic asthma. Our research group discovered that Mycoplasma pneumoniae, a common bacteria in the airway of asthmatics, produces a toxin that increases allergic inflammation and may result in the initiation or persistence of asthma. We have recently been funded for another 5 years to investigate the structure, function, immunologic response in both healthy and asthmatic subjects. This $5 million project plans to determine the role of this bacteria in chronic asthma and attempt to develop a vaccine that will induce neutralizing antibodies.
Additionally, I am actively involved with collaboration between UTHSCSA and UT Austin in the development of inhaled immunodulating drugs for the treatment of both asthma and pulmonary fibrosis. In collaboration with the Department of Cadiothoracic Surgery these therapies are also be tested for the prevention of rejection in a rodent model of lung transplantation.
College of Pharmacy
The University of Texas
2409 University Ave.
Austin, TX, USA
Email Address: pharmacy
Enhancing drug-delivery technologies can help in curing and treating diseases such as cancer, cardiovascular diseases, diabetes, fungal, respiratory and infectious diseases and treatment after organ transplants to prevent rejection.